Marksans Pharma Ltd.

BSE: MARKSANS524404ISIN INE750C01026

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹301.15-13.95 (-4.43%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹350.75
52W low: ₹156.00
Off 52W high: -14.14%
1M return: -9.16%
3M return: +11.33%
6M return: +53.37%
1Y return: +61.26%
20D avg volume: 98,084
50 DMA: ₹320.12
200 DMA: ₹241.86

Key ratios Consolidated

Market cap: ₹13,647 Cr
Current price: ₹301.15
52W high / low: ₹350.75 / ₹156.00
Face value: ₹1.00
P/E: 24.13
P/B: 4.10
EPS (TTM): ₹12.48
Book value / share: ₹73.54
ROE: —
ROCE: 17.50%
Operating margin: —
Net margin: —
Debt / equity: 0.01
Net debt: ₹-604.55 Cr
Interest cover: 24.24
Dividend yield: 0.30%
Dividend / share (TTM): ₹0.90
Payout: 7.21%
Cash conversion cycle: 158.3 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	940.17	840.80	856.11	754.43	720.41	619.99	70.85	681.85	641.92	590.62	560.01	586.13
	18.15	25.40	35.17	20.14	21.57	5.64	1.65	27.85	11.06	14.95	16.53	4.80
	958.32	866.20	891.29	774.57	741.98	625.63	72.50	709.70	652.98	605.57	576.54	590.93
	764.82	659.63	691.29	623.95	608.65	549.03	60.89	566.44	528.38	485.55	476.27	478.27
	231.49	220.67	264.97	273.82	227.72	192.69	18.81	189.26	214.38	161.31	148.38	192.87
	131.75	138.45	149.81	26.99	106.14	171.55	16.10	111.95	134.32	167.24	162.98	81.31
	122.31	114.29	106.76	111.99	103.80	98.39	9.72	88.44	84.16	80.48	79.75	74.53
	6.83	7.00	6.31	5.93	5.82	6.07	0.34	2.67	2.63	2.92	4.84	3.16
	32.11	24.86	24.29	24.33	26.92	23.10	2.27	20.69	19.51	20.44	21.05	22.00
	213.49	170.00	163.28	165.47	163.52	159.67	16.03	156.30	163.69	119.92	100.80	105.76
	193.50	206.57	200.00	150.62	133.33	76.60	11.61	143.26	124.60	120.02	100.28	112.66
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	193.50	206.57	200.00	150.62	133.33	76.60	11.61	143.26	124.60	120.02	100.28	112.66
	49.98	47.16	50.97	36.93	34.20	18.40	2.54	38.19	26.84	30.95	22.63	29.69
	143.53	159.41	149.03	113.69	99.14	58.20	9.07	105.07	97.76	89.07	77.64	82.97
	3.12	3.47	3.27	2.50	2.17	1.29	2.00	2.31	2.13	1.96	1.73	1.84
Key metrics
	232.44	238.43	230.60	180.88	166.07	105.77	14.22	166.62	146.74	143.38	126.17	137.82
	24.70%	28.40%	26.90%	24.00%	23.10%	17.10%	20.10%	24.40%	22.90%	24.30%	22.50%	23.50%
	15.30%	19.00%	17.40%	15.10%	13.80%	9.40%	12.80%	15.40%	15.20%	15.10%	13.90%	14.20%
	5.30%	—	6.20%	—	4.70%	—	4.30%	—	—	—	—	—
	30.50%	35.60%	1,108.30%	10.60%	12.20%	5.00%	-87.30%	16.30%	—	—	—	—
	44.80%	173.90%	1,543.10%	8.20%	1.40%	-34.70%	-88.30%	26.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	3,392	2,951	262.29	2,177	1,852	1,491
	98.86	82.53	7.04	50.42	59.31	41.85
	3,490	3,033	269.32	2,228	1,911	1,533
	2,740	2,473	218.93	1,804	1,574	1,285
	990.95	959.21	75.30	667.70	612.97	540.67
	447.00	454.49	57.45	444.28	314.78	163.25
	455.35	420.93	35.03	293.64	239.37	220.30
	26.07	24.12	1.17	11.20	9.13	8.45
	105.59	98.63	8.34	74.27	51.85	44.78
	712.24	651.95	60.02	387.07	352.09	294.84
	750.69	560.55	50.40	423.53	337.65	247.51
	0.00	0.00	0.00	0.00	0.00	0.00
	750.69	560.55	50.40	423.53	337.65	247.51
	185.04	140.49	12.13	108.63	72.33	60.70
	565.66	420.06	38.26	314.89	265.32	186.81
	12.36	9.22	8.40	6.92	6.41	4.51
Key metrics
	882.35	683.30	59.91	509.00	398.63	300.74
	26.02%	23.20%	22.80%	23.40%	21.50%	20.20%
	16.68%	14.20%	14.60%	14.50%	14.30%	12.50%
	—	17.50%	18.70%	—	—	—
	62.03%	1,025.10%	-88.00%	17.60%	24.20%	—
	108.36%	997.90%	-87.80%	18.70%	42.00%	—
	—	327.59	3.38	—	—	—
	—	1.09	0.54	—	—	—
	—	0.01	0.01	—	—	—
	—	-604.55	-47.27	—	—	—
	—	158.3	150.3	—	—	—
Balance sheet
	—	3,861	323.96	—	—	—
	—	2,723	220.41	—	—	—
	—	634.14	49.58	—	—	—
	—	644.57	54.00	—	—	—
	—	972.28	84.55	—	—	—
	—	—	9.78	—	—	—
	—	625.01	57.95	—	—	—
	—	336.91	30.57	—	—	—
	—	527.09	47.73	—	—	—
	—	29.59	2.31	—	—	—
	—	29.59	2.31	—	—	—
	—	0.00	0.00	—	—	—
	—	3,053	248.94	—	—	—
Cash flow
	—	458.12	20.67	—	—	—
	—	-248.27	-4.90	—	—	—
	—	-70.93	-6.51	—	—	—
	—	130.53	17.29	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	313.80	321.19	361.57	339.73	320.44	319.73	299.36	311.87	308.62	254.53	225.20	241.36
	57.24	17.47	27.48	15.86	58.19	2.01	7.82	22.51	31.36	8.15	12.19	1.32
	371.05	338.66	389.05	355.59	378.63	321.74	307.17	334.37	339.98	262.68	237.39	242.69
	270.83	248.20	264.69	273.47	257.14	258.17	257.27	259.65	263.64	220.38	198.99	208.09
	149.62	141.64	159.48	151.00	146.66	145.28	145.06	141.27	134.73	116.12	104.36	117.16
	14.78	18.03	13.26	16.02	20.99	22.80	16.77	23.33	30.97	30.99	20.39	22.11
	32.10	31.77	32.91	32.70	28.46	27.90	28.82	25.75	23.91	23.19	21.56	20.47
	0.34	0.34	0.35	0.36	0.32	0.30	0.31	0.30	0.28	0.28	0.23	0.27
	9.05	8.78	8.76	8.83	8.46	8.19	8.18	7.42	7.02	6.84	7.47	8.43
	63.29	49.46	47.34	58.38	54.43	56.99	55.84	55.94	67.29	49.65	47.11	41.10
	100.21	90.46	124.36	82.12	121.49	63.57	49.90	74.72	76.34	42.30	38.40	34.60
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	100.21	90.46	124.36	82.12	121.49	63.57	49.90	74.72	76.34	42.30	38.40	34.60
	14.67	21.42	32.44	21.20	21.69	15.52	12.31	19.26	13.13	10.28	5.41	9.31
	85.54	69.04	91.92	60.91	99.81	48.06	37.59	55.46	63.20	32.02	32.99	25.29
	1.89	1.52	2.03	1.34	2.20	1.06	0.83	1.22	1.39	0.71	0.73	0.56
Key metrics
	109.60	99.58	133.47	91.31	130.27	72.06	58.39	82.44	83.64	49.42	46.10	43.30
	34.90%	31.00%	36.90%	26.90%	40.70%	22.50%	19.50%	26.40%	27.10%	19.40%	20.50%	17.90%
	27.30%	21.50%	25.40%	17.90%	31.10%	15.00%	12.60%	17.80%	20.50%	12.60%	14.60%	10.50%
	5.60%	—	7.40%	—	8.00%	—	3.60%	—	—	—	—	—
	-2.10%	0.50%	20.80%	8.90%	3.80%	25.60%	32.90%	29.20%	—	—	—	—
	-14.30%	43.70%	144.50%	9.80%	57.90%	50.10%	13.90%	119.30%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,336	1,341	1,174	853.27	655.20	658.29
	118.05	103.53	69.83	62.07	60.48	42.25
	1,454	1,445	1,244	915.35	715.69	700.54
	1,057	1,053	1,001	743.45	583.65	566.03
	601.74	602.43	537.18	407.15	338.49	327.99
	62.09	73.06	102.06	79.03	66.14	45.71
	129.48	121.98	101.68	77.19	56.09	60.46
	1.39	1.33	1.17	0.99	3.61	3.79
	35.42	34.23	29.45	29.13	16.74	17.66
	218.47	217.15	228.71	157.21	112.76	106.52
	397.15	391.54	243.26	171.89	132.03	134.51
	0.00	0.00	0.00	—	—	—
	397.15	391.54	243.26	171.89	132.03	134.51
	89.73	90.84	54.99	38.13	29.17	30.52
	307.41	300.70	188.27	133.76	102.87	103.99
	6.78	6.64	4.15	2.95	2.48	2.54
Key metrics
	433.96	427.10	273.88	202.01	152.38	155.96
	32.47%	31.80%	23.30%	23.70%	23.30%	23.70%
	23.00%	22.40%	16.00%	15.70%	15.70%	15.80%
	—	23.30%	17.30%	—	—	—
	6.78%	14.20%	37.60%	30.20%	-0.50%	—
	27.60%	59.70%	40.80%	30.00%	-1.10%	—
	—	162.31	-88.89	—	—	—
	—	0.70	0.16	—	—	—
	—	0.00	0.00	—	—	—
	—	-91.25	-60.27	—	—	—
	—	171.9	171.3	—	—	—
Balance sheet
	—	1,994	1,755	—	—	—
	—	1,309	1,082	—	—	—
	—	91.25	60.27	—	—	—
	—	623.46	549.58	—	—	—
	—	189.13	205.21	—	—	—
	—	—	55.71	—	—	—
	—	368.68	353.59	—	—	—
	—	180.81	203.53	—	—	—
	—	310.25	345.63	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	1,652	1,383	—	—	—
Cash flow
	—	211.09	31.02	—	—	—
	—	-140.29	17.24	—	—	—
	—	-39.23	-29.92	—	—	—
	—	48.78	119.91	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +26.98%
Sales CAGR 5Y: —
Profit CAGR 3Y: +42.98%
Profit CAGR 5Y: —
Sales YoY (TTM): +6.78%
Profit YoY (TTM): +27.60%

Consolidated

Sales CAGR 3Y: +16.80%
Sales CAGR 5Y: —
Profit CAGR 3Y: +16.55%
Profit CAGR 5Y: —
Sales YoY (TTM): +62.03%
Profit YoY (TTM): +108.36%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 43.86%

Quarter	September 2026	June 2026
Promoter %	43.86%	43.87%

Holder	Type	Holding	Previous	Change
MARK SALDANHA	Promoter	43.80%	43.80%	0.00%
ORBIMED ASIA IV MAURITIUS FVCI LIMITED	Public	8.62%	8.62%	0.00%
UTI-HEALTHCARE FUND	Public	1.66%	2.11%	-0.45%
Schenelle Megan Saldanha	Promoter Group	0.03%	—	—
SANDRA SALDANHA	Promoter	0.02%	0.07%	-0.05%
Merrill Jean Saldanha	Promoter Group	0.01%	—	—
Marise Ann Saldanha	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Marksans Pharma Ltd.	13,647	301.15	24.13	17.50%	+62.03% TTM	+108.36% TTM	+61.26%

Filings & corporate actions

Recent announcements

Allotment of Equity Shares under Marksans Employees Stock Option Scheme 20244 Nov 2026 · Company Update / Allotment of ESOP / ESPS
Press Release for Financial Results Q2FY274 Nov 2026 · Company Update / Press Release / Media Release
Investor Presentation Q2FY274 Nov 2026 · Company Update / Investor Presentation
Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30 September 20264 Nov 2026 · Result / Financial Results
Please find attached outcome of the Board meeting held on 04 November 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
Intimation of schedule for Q2FY27 Earnings Conference Call26 Oct 2026 · Company Update / Analyst / Investor Meet
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Unaudited Financial Results ....19 Oct 2026 · Board Meeting / Board Meeting
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter and half year ended September 30, 202613 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Intimation of Closure of Trading Window for the quarter and half year ended 30 September, 202625 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Notice to Shareholders regarding re-opening of Special Window for Re-lodgement of transfer requests of Physical Shares17 Sep 2026 · Company Update / General
Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of the Company to the IEPF7 Sep 2026 · Company Update / Newspaper Publication
Intimation of schedule of Investors Meet1 Sep 2026 · Company Update / Analyst / Investor Meet
Please find attached the voting result of the 34th AGM27 Aug 2026 · Company Update / General
Scrutinizer''s Report along with voting result for the 34th AGM27 Aug 2026 · AGM/EGM / AGM
Proceeding of 34th Annual General Meeting of the Company held today27 Aug 2026 · AGM/EGM / AGM
Please find attached disclosure on ESG rating26 Aug 2026 · Company Update / General
Transcript of Investors/Analyst meet on Q1 FY 27 Financial Results20 Aug 2026 · Company Update / Earnings Call Transcript
Audio Recording of investor(s)/analyst(s) meet Conference Call on Q1 FY 27 Financial Results13 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Publication for Unaudited Financial Results for the quarter ended June 30, 202613 Aug 2026 · Company Update / Newspaper Publication
Press Release for Financial Results Q1 FY 2712 Aug 2026 · Company Update / Press Release / Media Release
Investor Presentation Q1 FY 2712 Aug 2026 · Company Update / Investor Presentation
The Board in its meeting held on 12 August 2026 approved Financial Results for the quarter ended June 30, 202612 Aug 2026 · Result / Financial Results
The Board in its meeting held on 12 August 2026 approved the Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter ended June 30, 202612 Aug 2026 · Board Meeting / Outcome of Board Meeting
Please find attached newspaper publication for Annual General Meeting Notice6 Aug 2026 · Company Update / Newspaper Publication
Please find enclosed the BRSR4 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find attached herewith the Annual Report for the Financial Year 2025-264 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 34th Annual General Meeting of the Company proposed to be held on 27 August 20264 Aug 2026 · AGM/EGM / AGM
Intimation of schedule for Q1FY27 Earnings Conference Call3 Aug 2026 · Company Update / Analyst / Investor Meet
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Quarterly Results For The Quarter ....31 Jul 2026 · Board Meeting / Board Meeting
Newspaper Publication for AGM Intimation30 Jul 2026 · Company Update / Newspaper Publication
Update on acquisition of 100 percent share capital of ABCnow GmbH.20 Jul 2026 · Company Update / General
Second 100 Day Campaign - "Saksham Niveshak" Phase IV17 Jul 2026 · Company Update / General
Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 202610 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Marksans Pharma signed a definitive agreement to acquire 100 percent share capital of a German based Company namely ABCnow GmbH8 Jul 2026 · Company Update / Press Release / Media Release
Pl find attached announcement related to record date for payment of dividend, AGM date and dividend payment date.3 Jul 2026 · Corp Action / Date of payment of Dividend
The Board of Directors of Marksans Pharma Limited fixed 20 August 2026 as the Record Date for payment of dividend.3 Jul 2026 · Corp Action / Dividend Updates
The Board of Directors of Marksans Pharma Limited in its meeting held on 3 July 2026 fixed 27 August 2026 as the Annual General Meeting.3 Jul 2026 · AGM/EGM / AGM
20 August 2026 is fixed as Record Date for payment of dividend.3 Jul 2026 · Corp. Action / Record Date
The Board in its meeting approved the AGM related matters and fixed 27 August 2026 as the AGM of the Company3 Jul 2026 · Others / Outcome without intimation
Intimation of Closure of Trading Window for the quarter ended June 30, 202626 Jun 2026 · Insider Trading / SAST / Closure of Trading Window

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.9000	20 Aug 2026	20 Aug 2026	—
Final Dividend - Rs. - 0.8000	1 Aug 2025	1 Aug 2025	—
Final Dividend - Rs. - 0.6000	17 Sep 2024	17 Sep 2024	—

Board meetings

4 Nov 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results